1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Relapsed Refractory Multiple Myeloma (RRMM): new trials by email Literature Review of Relapsed Refractory Multiple Myeloma (RRMM) trials Research Report on Relapsed Refractory Multiple Myeloma (RRMM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma Linvoseltamab, Elotuzumab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 410 | 2023-09-18 | 2026-10-07 |
Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
Calcium Dobesilate (1) · Dexamethasone (1) · elotuzumab (1) · pomalidomide (1)
Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Singapore (1) · South Korea (1) · Spain (1)